- Home
- VRCA vs KLRS Comparison
VRCA vs KLRS Comparison
Compare VRCA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- KLRS
- Stock Information
- Founded
- VRCA 2013
- KLRS 2019
- Country
- VRCA United States
- KLRS United States
- Employees
- VRCA N/A
- KLRS N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- KLRS Health Care
- Exchange
- VRCA Nasdaq
- KLRS Nasdaq
- Market Cap
- VRCA 43.0M
- KLRS 129.0M
- IPO Year
- VRCA 2018
- KLRS N/A
- Fundamental
- Price
- VRCA $0.42
- KLRS $4.06
- Analyst Decision
- VRCA Hold
- KLRS Buy
- Analyst Count
- VRCA 5
- KLRS 1
- Target Price
- VRCA $6.00
- KLRS N/A
- AVG Volume (30 Days)
- VRCA 243.3K
- KLRS 62.9K
- Earning Date
- VRCA 05-13-2025
- KLRS 05-19-2025
- Dividend Yield
- VRCA N/A
- KLRS N/A
- EPS Growth
- VRCA N/A
- KLRS N/A
- EPS
- VRCA N/A
- KLRS N/A
- Revenue
- VRCA $7,566,000.00
- KLRS N/A
- Revenue This Year
- VRCA $127.58
- KLRS N/A
- Revenue Next Year
- VRCA $88.06
- KLRS N/A
- P/E Ratio
- VRCA N/A
- KLRS N/A
- Revenue Growth
- VRCA 47.66
- KLRS N/A
- 52 Week Low
- VRCA $0.38
- KLRS $4.19
- 52 Week High
- VRCA $11.41
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- VRCA 39.53
- KLRS N/A
- Support Level
- VRCA $0.45
- KLRS N/A
- Resistance Level
- VRCA $0.48
- KLRS N/A
- Average True Range (ATR)
- VRCA 0.04
- KLRS 0.00
- MACD
- VRCA -0.00
- KLRS 0.00
- Stochastic Oscillator
- VRCA 22.13
- KLRS 0.00
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.